MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

09 Mar 2023 Evaluate

Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg. In this regard, the company has enclosed its press release.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

821.60 7.25 (0.89%)
21-Aug-2026 10:36 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1895.10
Dr. Reddys Labs. 1180.60
Cipla 1427.35
Lupin 2202.00
Zydus Lifesciences 1105.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: